Vaginal Squamous Cell Carcinoma
Associated Genetic Biomarkers
There are 5 clinical trials for vaginal squamous cell carcinoma, of which 4 are open and 1 is completed or closed. Of the trials that contain vaginal squamous cell carcinoma as an inclusion criterion, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (2 open), 1 is phase 2 (1 open), and 1 is phase 3 (0 open).
CDKN2A and HPV are the most frequent gene inclusion criteria for vaginal squamous cell carcinoma clinical trials .
Atezolizumab, avelumab, and bevacizumab are the most common interventions in vaginal squamous cell carcinoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.